

RESEARCH ARTICLE

Bioavailability of *n*-3 fatty acids from *n*-3-enriched foods and fish oil with different oxidative quality in healthy human subjects: a randomised single-meal cross-over study

Inger Ottestad^{1,2,3}, Berit Nordvi⁴, Gjermund Vogt⁵, Marianne Holck¹, Bente Halvorsen^{3,6}, Kirsti W. Brønner⁴, Kjetil Retterstøl^{2,3,7}, Kirsten B. Holven^{2,3,8}, Astrid Nilsson⁹ and Stine M. Ulven^{1,2,3*}

¹Department of Health, Nutrition and Management, Faculty of Health Sciences, Oslo and Akershus University College of Applied Sciences, PO Box 4 St. Olavs plass, 0130 Oslo, Norway

²Department of Nutrition, Institute for Basic Medical Sciences, University of Oslo, PO Box 1046 Blindern, 0317 Oslo, Norway

³Faculty of Medicine, University of Oslo, Oslo, Norway

⁴TINE SA, R&D Centre, PO Box 7 Kalbakken, 0902 Oslo, Norway

⁵Eurofins Food & Feed Testing Norway AS, Møllebakken 40, 1538 Moss, Norway

⁶Research Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet, PO Box 4950 Nydalen, 0424 Oslo, Norway

⁷Lipid Clinic, Medical Department, Oslo University Hospital, Rikshospitalet, PO Box 4950 Nydalen, 0424 Oslo, Norway

⁸Department of Endocrinology, Morbid Obesity and Preventive Medicine, Norwegian National Advisory Unit on Familial Hypercholesterolemia, Oslo University Hospital, Rikshospitalet, PO Box 4950 Nydalen, 0424 Oslo, Norway

⁹Nofima AS, Norwegian Institute of Food, Fisheries and Aquaculture Research, Osloveien 1, 1430 Ås, Norway

(Received 2 March 2016 – Final revision received 12 August 2016 – Accepted 16 August 2016)

Journal of Nutritional Science (2016), vol. 5, e43, page 1 of 8

doi:10.1017/jns.2016.34

Abstract

Regular consumption of long-chain *n*-3 fatty acids (LC *n*-3 FA) reduces postprandial triacylglycerolaemia. Functional foods and supplements are alternative sources of LC *n*-3 FA; however, emulsification technologies, food matrices and altered lipid oxidation levels affect their bioavailability. Moreover, which functional foods are optimal LC *n*-3 FA carriers is unknown. The aim of the study was to determine the bioavailability of LC *n*-3 FA and the postprandial TAG response after the intake of oxidised or non-oxidised cod liver oil and after the intake of emulsified or non-emulsified LC *n*-3 FA using novel functional food items as LC *n*-3 FA carriers in a randomised cross-over acute study. A total of twenty-four healthy subjects completed the study in which subjects consumed one of four different test meals containing 1.5 g LC *n*-3 FA, or a control meal with no LC *n*-3 FA. Postprandial TAG-rich lipoproteins were isolated and their fatty acid composition was measured. The LC *n*-3 FA from emulsified foods were more rapidly incorporated into TAG-rich lipoproteins compared with non-emulsified foods. The incorporation of LC *n*-3 FA was similar for oils emulsified in yogurt or juice and was unaffected by the oxidative status of the oil. Postprandial TAG levels did not differ among the various test meals. In conclusion, emulsification increases the bioavailability of LC *n*-3 FA through a more rapid incorporation into TAG-rich lipoproteins, and juice and yogurt are equally suited as LC *n*-3 FA carriers. The acute intake of oxidised cod liver oil does not influence the incorporation of LC *n*-3 FA into TAG-rich lipoproteins.

Key words: Fish oil: Oxidised fish oil: *n*-3-Enriched food: Cross-over studies: EPA: DHA: Postprandial TAG

Abbreviation: LC *n*-3 FA, long-chain *n*-3 fatty acid.

* **Corresponding author:** S. M. Ulven, email smulven@medisin.uio.no



Regular consumption of fish and fish oil supplements containing long-chain *n*-3 fatty acids (LC *n*-3 FA) reduces fasting and postprandial TAG levels^(1–3). It is well known that postprandial hypertriglycerolaemia significantly affects the development and progression of atherosclerosis^(4–6). In addition, postprandial hypertriglycerolaemia is an independent risk factor for adverse cardiovascular events and death^(7–9).

Dietary sources of LC *n*-3 FA are scarce and the food industry uses different food technologies, such as emulsification, to incorporate LC *n*-3 FA into a variety of novel functional foods to increase their availability to consumers. Studies have shown that the bioavailability (digestion and absorption) of LC *n*-3 FA is affected by the chemical forms of LC *n*-3 FA (i.e. TAG, phospholipids, ethyl esters), by emulsification and by the concomitant intake of foods, especially fat (the food matrix effect)^(10–12). It is still unclear which food items are best suited as LC *n*-3 FA carriers, in terms of providing optimal bioavailability of LC *n*-3 FA and a postprandial TAG response.

LC *n*-3 FA are highly susceptible to lipid oxidation⁽¹³⁾, but no international legislation standard for fish oil quality, defined as maximum oxidation level, has been established for fish oil used for human consumption^(14,15). Recent studies have reported elevated peroxide levels in commercialised fish oil capsules, which have led to some concern that regular consumption of oxidised marine oils may negatively affect human health^(16–21). In a previous study, we did not observe any changes in fasting plasma LC *n*-3 FA levels, lipids or several other oxidative stress markers after 7 weeks of consumption of oxidised compared with non-oxidised fish oil⁽²²⁾. However, another study reported that the intake of less oxidised *n*-3 FA supplements for 30 d reduced blood lipids and blood pressure compared with highly oxidised LC *n*-3 FA supplements⁽²³⁾. Postprandial studies have also shown that the intake of oxidised compared with non-oxidised vegetable oils increased lipid peroxides in chylomicrons^(24–26). Lipid oxidation products are highly reactive and can form stable covalent adducts with macromolecules such as proteins and lipids. Thus, the absorption of fatty acids and the enzymes involved in the lipoprotein assembly could potentially be affected by intake of oxidised lipids^(27,28). Whether consumption of oxidised *v.* non-oxidised fish oil alters the bioavailability of LC *n*-3 FA has not been previously investigated in human subjects.

The aims of the present study were to investigate the bioavailability of LC *n*-3 FA and the postprandial TAG response after intake of oxidised *v.* non-oxidised cod liver oil and after the intake of equal amounts of emulsified *v.* non-emulsified LC *n*-3 FA in healthy human subjects using novel functional food items as carriers of LC *n*-3 FA (yogurt *v.* juice).

Materials and methods

Subjects

Healthy non-smoking men and women aged 20–50 years (*n* 32) were recruited from the Akershus University College, Norway. Subjects that had a fish consumption \geq two servings per week or used cod liver oil/fish oil supplements >1 /week were excluded. Other exclusion criteria included chronic diseases and

diseases known to interfere with lipid absorption such as lactose intolerance and other malabsorption diseases. In addition, subjects with circulating levels of total cholesterol >7.5 , TAG >4 mmol/l, C-reactive protein ≥ 10 mmol/l and thyroid-stimulating hormone, triiodothyronine and thyroxine above or below the normal reference ranges were excluded. Furthermore, hypertension ($\geq 160/100$ mmHg), BMI ≥ 35 kg/m², change in body weight during the last 3 months (weight ± 5 %), pregnancy and lactation were also used as exclusion criteria. The use of lipid-lowering and antihypertensive medications, and the use of dietary supplements known to interfere with plasma cholesterol such as soluble fibre and plant sterols were not permitted during the study period. The study was approved by the Regional Committee of Medical Ethics (approval no. 1.2007.2870) and by the Norwegian Social Science Data Services (approval no. 18790). Written informed consent for participation was obtained from each participant and the study complied with the Declaration of Helsinki.

Study design

The study was a randomised five-period cross-over study. The participants were randomised into five groups each receiving a test meal every second week. In total, all participants received the five test meals. Each test meal consisted of similar amounts of yogurt (203 g), juice (324 g), bread (50 g), butter (3.2 g) and an oil shot (7.9 g). The test meals contained 1.5 g EPA+DHA from either (A) emulsified LC *n*-3 FA in yogurt, (B) emulsified LC *n*-3 FA in juice, (C) non-emulsified, non-oxidised LC *n*-3 FA as an oil shot or (D) non-emulsified, oxidised LC *n*-3 FA as an oil shot, or (E) a reference test meal containing no LC *n*-3 FA. All test meals were prepared with different types of oils, which are further outlined in Table 1. The energy content, and the percentage of energy (E %) from carbohydrates (43.9 E %), proteins (7.7 E %) and total fat (48.4 E %) were equal in all test meals. The composition of the fatty acids in the test meals is shown in Supplementary Table S1.

Blocked randomisation was used to divide the subjects into five groups, and the participants received the test meals in one of the five fixed orders (group 1: ABCDE, group 2: BCDEA, group 3: CDEAB, group 4: DEABC, group 5: EABCD). The flow of subjects through the study is outlined in Fig. 1. The study was blinded for the participants and all study investigators involved, except for those preparing and serving the test meals. During the study period, the subjects were encouraged to have a stable diet and a fish intake as reported at inclusion. The last 2 d prior to the test day, the subjects were not allowed to consume fish or other fish products containing marine LC *n*-3 FA. A dietitian provided information about which food products they should avoid. During the test day, the subjects were not allowed to use chewing tobacco, coffee, tea or chewing gum, but water was allowed *ad libitum* throughout the day. The test meals were eaten at the University College under observation, and all foods and beverage were consumed within 20 min.

Preparation of test products

Preparation of emulsified long-chain *n*-3 oil in yogurt and juice. Yogurt and juice enriched with LC *n*-3 FA were

**Table 1.** Type of oil added to the five test meals

Food item	Oil type	Test meal				
		A Yogurt meal	B Juice meal	C Oxidised cod liver oil meal	D Non-oxidised cod liver oil meal	E Reference meal
Yogurt, emulsified	Cod liver	X	–	–	–	–
	High-oleic sunflower	–	X	X	X	X
Juice, emulsified	Cod liver	–	X	–	–	–
	High-oleic sunflower	X	–	X	X	X
Oil shot	Cod liver	–	–	X*	X*	–
	High-oleic sunflower	X	X	–	–	X

PV, peroxide value; AV, anisidine value.

* The cod liver oil was oxidised (PV 16 meq/kg; AV 11) in test meal C, and non-oxidised (PV 1.5 meq/kg; AV 2.1) in test meal D, respectively. Yogurt and juice were emulsified with cod liver oil or high-oleic sunflower oil to make test and control food items, respectively.

produced by mixing commercial yogurt (162 g; 3.4 % fat) or juice (284 g; 0.2 % fat) with emulsions (40.5 g) containing functional food-grade cod liver oil (7.9 g) to make test foods with 1.5 g EPA + DHA. Matching control foods containing no LC *n*-3 FA were prepared by adding similar amounts of emulsion (40.5 g) with high-oleic sunflower oil (7.9 g) to the commercial yogurt or juice. The final fat content of the yogurt and juice was similar for test and control. The fat content and the macronutrient composition of the food items prepared and included in the test meals are outlined in Table 2. Food products were prepared and delivered by TINE SA, and the functional food-grade cod liver oil and the high-oleic sunflower oil were provided by TINE SA

(*Gadidae* sp., EPADHA Oil 1200) and AarhusKarlshamn AB, respectively.

Preparation of oxidised cod liver oil. Functional food-grade cod liver oil (*Gadidae* sp.) was oxidised at Nofima Mat (Ås, Norway) as described elsewhere⁽²²⁾. Briefly, the batch with high-quality non-oxidised oil was divided into two parts. The non-oxidised oil had peroxide value and anisidine value of 1.5 meq/kg and 2.1, respectively (measured according to AOCS Official Method Cd 8–53 and Cd 18–90, respectively). The oxidised oil was placed at room temperature and oxygenated until the oil was oxidised to a




Fig. 1. Flow diagram showing the flow of participants through the trial. The participants were randomised into five groups in which the five test meals (A, B, C, D and E) were consumed in a predetermined sequence. Two participants were lost to follow-up after day 0 due to discomfort (one in group 1 and one in group 2), and one was excluded after day 0 due to not meeting the inclusion criteria (group 3).

**Table 2.** Macronutrient composition of the food items used in the test meals

Macronutrients	Yogurt*		Juice*		Oil shot†		Butter		Bread	
	203 g/meal		324 g/meal		7.9 g/meal		3.2 g/meal		50 g/meal	
	g/100 g	g/food item	g/100 g	g/food item	g/100 g	g/food item	g/100 g	g/food item	g/100 g	g/food item
Carbohydrates	12.2	19.8	10.4	29.5	0.0	0.0	0.5	0.0	44.6	22.3
Protein	3.6	5.8	0.7	2.0	0.0	0.0	0.5	0.0	9.4	4.7
Fat	7.1	14.4	2.9	9.5	7.9	7.9	82.0	2.6	1.4	0.7

* The yogurt and juice meals were made by adding 40.5 g emulsion containing either cod liver oil or high-oleic sunflower oil to 162 g yogurt and 283.5 g juice.

† Macronutrient composition of non-oxidised, oxidised and high-oleic sunflower oil shots.

peroxide value of 16 meq/kg and an anisidine value of 11. The characterisation of the fish oils is outlined in Table 3.

Blood samples

The day prior to blood sampling, the subjects were told to refrain from alcohol consumption and vigorous physical activity, and the subjects were instructed to consume a low-fat meal during the afternoon and evening. Venous blood samples were drawn after an overnight fast (≥ 12 h) and at 2, 4 and 6 h after consumption of the test meals. Serum was obtained from silica gel tubes (BD Vacutainer) and kept at room temperature for 30–120 min and then centrifuged at 1500 *g* for 12 min at 4°C. Serum total, LDL- and HDL-cholesterol, TAG, glucose, C-reactive protein, alanine transaminase (ALT), creatinine, thyroid-stimulating hormone, triiodothyronine and thyroxine were measured by standard methods at Fürst Medical Laboratory (Oslo, Norway). Plasma was obtained from heparin vacuum tubes (BD Vacutainer) and was immediately centrifuged at 1300 *g* for 10 min at 4°C. Plasma was then isolated, and sucrose was added to a final 0.6 % sucrose solution before freezing (-80°C). Samples were analysed for fatty composition in TAG-rich lipoproteins within 6 months of freezing.

Lipoprotein isolation

TAG-rich lipoproteins; chylomicrons (CM) and VLDL (d 1.006 kg/l (g/ml), were isolated from plasma by sequential ultracentrifugation using a TI 80 rotor (Beckman Optima

LE-80K ultracentrifuge), using soluble sodium bromide (NaBr) to adjust the final volume. Plasma was centrifuged at 570 000 *g* for 5 h and 15 min at 10°C, and the TAG-rich fraction (CM + VLDL) was harvested, N₂ flushed, snap frozen and stored at -80°C until further analysis.

Fatty acid analysis of TAG-rich lipoprotein fraction

Lipids in the TAG-rich lipoprotein fraction were extracted using the method of Bligh & Dyer⁽²⁹⁾. The fatty acids in extracts and oils were transmethylated by a modified version of a method described by Mason and Waller. Briefly, 1 μl of the methyl ester solution was injected splitless on a GC (HP model no. G1530A) equipped with an autosampler (HP 6890 Series Injector) and flame ionization detector. The analytes were separated on a BPX70 column (0.25 mm internal diameter, 60 m, 0.25 μm film) from SGE with He as the carrier gas, using a temperature program of 70°C for 1 min, increasing by 30°C/min to 170°C, then by 1.5°C/min to 200°C and by 3°C/min to 220°C with a final hold time of 5 min. Peaks were integrated with HP GC ChemStation software (rev. B.0101; Agilent Technologies) and identified by use of external standards. CV were $<5\%$.

Fatty acid analysis of food

Lipids in the foods were extracted using a modified method of Bligh & Dyer⁽²⁹⁾. The fatty acids in extracts and oils were transmethylated and 1 μl of the methyl ester solutions was injected splitless on a GC (Agilent GC-6890N; Agilent Technologies) equipped with an autosampler (Agilent G-2614A) and flame ionization detector. The analytes were separated on a HP-88 column (0.25 mm internal diameter, 100 m, 0.20 μm film) from Agilent with He as the carrier gas, using a temperature program of 60°C for 10 min, increasing by 10°C/min to 170°C, and by 2.0°C/min to 216°C and with a final hold time of 35 min. Peaks were integrated with HP GC ChemStation software (rev. B.0101; Agilent Technologies) and identified by use of external standards. CV were $<5\%$.

Statistical analysis

Sample size was calculated from a pilot study in which six subjects were included. To detect a 40 % difference in EPA (change from baseline between groups), using 80 % power

Table 3. Characterisation of the oils

	Non-oxidised cod liver oil	Oxidised cod liver oil	High-oleic sunflower oil
Fatty acids			
SFA (g/100 g)	16	16	7
MUFA (g/100 g)	47	47	76
PUFA (g/100 g)	28	28	9
n-3 Fatty acids			
EPA (20 : 5n-3) (g/100 g)	9	9	0
DHA (22 : 6n-3) (g/100 g)	11	11	0
DPA (22 : 5n-3) (g/100 g)	1.0	1.0	0.0
ALA (18 : 3n-3) (g/100 g)	0.8	0.8	0.3
Oxidation level			
PV (meq/kg)	1.5	16	4
AV	2.1	11	3
Totox*	5.1	43	11

DPA, docosapentaenoic acid; ALA, α -linolenic acid; PV, peroxide value; AV, anisidine value.

* Totox = $2 \times \text{PV} + \text{AV}$.



and 0.05 level of significance (two-sided), a total of twenty subjects were suggested to be necessary. A 20 % dropout was expected; therefore a total of twenty-five subjects were included. Parametric statistics were used and data are presented as mean values with standard deviations or standard errors. Repeated ANOVA measurements with Bonferroni *post hoc* analysis were used to compare differences among the test meals at each time point. All analyses were performed using SPSS for Windows (version 20; SPSS, Inc.).

Results

In all, twenty-four subjects (six men and eighteen women) aged 32 ± 8 years and with blood lipid levels within the normal range completed the study (Table 4).

The postprandial concentrations of EPA and DHA in TAG-rich lipoproteins were significantly different after the intake of test meals where LC *n*-3 FA were emulsified in juice or yogurt, compared with the intake of test meals where the LC *n*-3 FA were given as non-emulsified cod liver oil (Figs 2 and 3). Compared with baseline, the levels of EPA and DHA in TAG-rich lipoproteins were significantly increased after 2 and 4 h and reached a maximum level 4 h after consumption of test meals containing LC *n*-3 FA-enriched juice and yogurt ($P < 0.001$ for all comparisons). No significant differences between juice and yogurt were observed for EPA or DHA levels at any time point. Despite approximately similar content of EPA (9 %) and DHA (11 %) in the fish oil, the relative increase of EPA was higher compared with that of DHA, at 2 and 4 h after intake (Figs 2 and 3). EPA levels decreased significantly between 4 and 6 h after intake of emulsified juice and yogurt ($P = 0.001$ and $P < 0.001$, respectively); however, DHA levels remained unchanged between 4 and 6 h ($P = 0.141$ and $P = 0.676$, respectively). Similar time–response curves for EPA and DHA levels in TAG-rich lipoproteins after the intake of test meals containing non-emulsified cod liver oil shots (oxidised and non-oxidised) were observed. Compared with baseline, a significant increase in both EPA and DHA levels were only observed after 6 h ($P < 0.001$ for all comparisons) (Figs 2 and 3). No significant differences in EPA or DHA levels were observed between the intake of oxidised and non-oxidised cod liver oil at any of the time points.

Table 4. Baseline characteristics* (Mean values and 2 standard deviations)

	Mean	2 SD
Subjects (<i>n</i>)		
Male	6	
Female	18	
Age (years)	32	8
BMI (kg/m ²)	24	3
Glucose (mmol/l)	4.7	0.5
Total cholesterol (mmol/l)	5.0	1.1
LDL-cholesterol (mmol/l)	2.8	0.9
HDL-cholesterol (mmol/l)	1.6	0.4
TAG (mmol/l)	0.8	0.4

* Data were collected at baseline before the first test day.




Fig. 2. Percentage of EPA in total lipids from the TAG-rich lipoprotein fraction (chylomicrons/VLDL) at baseline and after 2, 4 and 6 h after intake of test meals containing 1.5 g EPA + DHA in either emulsified juice or yogurt, non-oxidised cod liver oil, oxidised cod liver oil or reference oil lacking EPA or DHA. Values are means, with standard errors represented by vertical bars. * $P < 0.001$ for juice and yogurt compared with baseline. † $P = 0.007$ for non-oxidised cod liver oil and $P < 0.001$ for oxidised cod liver oil compared with baseline.

When comparing all test meals, significantly higher EPA and DHA levels were observed at 2 and 4 h after intake of LC *n*-3 FA-enriched juice and yogurt, compared with cod liver oil shots (oxidised or non-oxidised; $P < 0.001$ for all comparisons). At 6 h, the EPA levels were significantly increased compared with the reference meal ($P < 0.001$ for all comparisons), but they were similar among the different test meals. However, 6 h after intake, the levels of DHA were significantly higher after consumption of LC *n*-3 FA-enriched yogurt and juice, compared with that of oxidised cod liver oil ($P = 0.007$ and $P = 0.012$, respectively). In addition, a significantly higher DHA level was observed 6 h after of LC *n*-3 FA-enriched yogurt, but not juice, compared with the intake of non-oxidised cod liver oil ($P = 0.048$).

No significant differences in serum TAG levels were observed among the five test meals at baseline or postprandially at any time point. For all test meals, the postprandial serum TAG levels were significantly increased after 2 h (within-group analysis $P < 0.001$ for all test meals) and 4 h (for all test meals; $P < 0.05$); the maximum level was reached 2 h after intake (Table 5). Correlation analysis for each of the test meals was performed to determine if fasting TAG levels were associated with serum postprandial TAG levels. No correlation between fasting TAG levels (mmol/l) and the relative




Fig. 3. Percentage of DHA in total lipids from the TAG-rich lipoprotein fraction (chylomicrons/VLDL) at baseline and after 2, 4 and 6 h after intake of test meals containing 1.5 g EPA + DHA in either emulsified juice or yogurt, non-oxidised cod liver oil, oxidised cod liver oil or reference oil lacking EPA or DHA. Values are means, with standard errors represented by vertical bars. * $P < 0.001$ for juice and yogurt compared with baseline. † $P < 0.001$ for non-oxidised and oxidised cod liver oil compared with baseline.



Table 5. Serum TAG (mmol/l) before and after intake of each test meal (Mean values and standard deviations)

Time...	0 h		2 h		4 h		6 h	
	Mean	SD	Mean	SD	Mean	SD	Mean	SD
Emulsified <i>n</i> -3 juice	0.8	0.5	1.4**	0.8	1.1*	0.8	0.9	0.6
Emulsified <i>n</i> -3 yogurt	0.8	0.5	1.4**	0.9	1.2*	1.0	0.9	0.7
Oxidised cod liver oil	0.9	0.4	1.5**	0.8	1.2*	0.8	1.0	0.6
Non-oxidised cod liver oil	0.9	0.5	1.5**	0.9	1.3*	0.9	1.0	0.7
Reference oil	0.8	0.4	1.4**	0.7	1.3*	0.8	1.0	0.6

Mean value was significantly different from that at baseline: * $P < 0.05$, ** $P < 0.001$.

increase in TAG levels (%) was observed among the different test meals at any time point (data not shown). Finally, no correlations were observed between EPA or DHA levels in TAG lipoproteins and the postprandial increase in serum TAG (%) at any time point (data not shown).

Discussion

The present study shows that EPA and DHA from food items containing emulsified LC *n*-3 FA are more quickly incorporated into TAG-rich lipoproteins compared with non-emulsified LC *n*-3 FA. Neither the oxidative status (oxidised *v.* non-oxidised oils) nor the food matrix (LC *n*-3 FA-enriched juice or yogurt) influenced the incorporation of LC *n*-3 FA into TAG-rich lipoproteins. The postprandial rise in serum TAG did not differ among the test meals.

Several long-term human studies have shown that the bioavailability EPA and DHA from fish oil capsules is influenced by the chemical form of LC *n*-3 FA^(10–12,30). In line with our results, other acute studies have reported a more rapid absorption from food items with emulsified LC *n*-3 FA^(31–35). One possible explanation is that emulsified oils bypass the normal physiological digestion process, in which fat globules are broken down into smaller emulsion droplets⁽³²⁾. Another possibility is that emulsification of the oil reduces droplet size, causing them to be more dispersed, which leads to increased pancreatic lipase activity⁽³⁶⁾. Thus, increased pancreatic lipase activity may explain, at least in part, the rapid incorporation of EPA and DHA into TAG-rich lipoproteins after intake of food items containing emulsified LC *n*-3 FA. Emulsification of marine oils improves palatability and tolerance (remove ‘fishy flavour’), making the oils suitable for fortified food production. However, the food matrix (the food texture and the fat content of the food) may affect the digestion and the incorporation of LC *n*-3 FA in chylomicrons. In contrast to our study, a more rapid absorption of LC *n*-3 FA after intake of yogurt was observed when the same amount of emulsified fish oil was added to either yogurt or a fitness bar⁽³¹⁾. The authors suggested that the solid food matrix of the fitness bar prevented the release of LC *n*-3 FA during digestion⁽³¹⁾. The semi-liquid of yoghurt and liquid form of juice may explain the similar and rapid release of LC *n*-3 FA observed in the present study.

LC *n*-3 FA from oxidised compared with non-oxidised oils were similarly incorporated into TAG-rich lipoproteins. This

result is in line with our previous study where the plasma levels of EPA and DHA were similar after 7 weeks of intake of oxidised compared with non-oxidised cod liver oil capsules⁽²²⁾. Despite differences in lipid oxidation products in the oxidised and non-oxidised cod liver (measured by peroxide value and anisidine value; Table 1), the concentration of EPA and DHA was equal in the oils. Thus, the level of oxidation of cod liver oil did not affect the incorporation rates of EPA and DHA into TAG-rich lipoproteins.

We did not observe any effect of LC *n*-3 FA intake on postprandial TAG levels. Studies in normo- and hypertriglycerolaemic subjects have shown that regular consumption of LC *n*-3 FA reduces postprandial TAG levels^(37–39); however, decreases in postprandial TAG levels have not been observed in acute studies of normotriglycerolaemic subjects^(3,31,40). The stable fish consumption (≤ 2 meals/week) among some of the participants over the last 4 months prior to inclusion and throughout the study period may have influenced the postprandial TAG results in the present study. Moreover, we cannot rule out that the results would have been different in a study group with a lower baseline consumption of LC *n*-3 FA. A limitation of our study is that the absolute availability of LC *n*-3 FA could not be compared because we did not take blood samples beyond 6 h.

In conclusion, the present study demonstrates that emulsification of cod liver oil increases the bioavailability of EPA and DHA by more rapidly incorporating them into TAG-rich lipoproteins. We also found that juice and yogurt were equally effective as LC *n*-3 FA carriers. Furthermore, the present study provides additional evidence that the acute intake of oxidised cod liver oil does not influence the incorporation of LC *n*-3 FA into TAG-rich lipoproteins.

Supplementary material

The supplementary material for this article can be found at <https://doi.org/10.1017/jns.2016.34>

Acknowledgements

We thank Ellen Raael, Grete Skjeggstad and Oddlaug Ledsaak at Akershus University College, Lars Røkke and Bente Serigstad at TINE SA, R&D Centre, and Lene Ruud Lima and Stine Grimmer at Nofima for practical help during the study. We also thank Professor Jason Matthews for reading and editing the manuscript. This study was supported by



TINE SA, Centre for Research and Development, PO Box 7, Kalbakken, N-0902 Oslo Norway and The Research Council of Norway (PO Box 2700, St. Hanshaugen, N-0131 Oslo) and Akershus University College. The cod liver oil used in this study, TINE EPADHA Oil 1200, was produced by Martitex AS, (Havnegata 17, 8400 Sortland, Norway) and provided by TINE SA. Martitex AS was at the present time a fully owned subsidiary of TINE SA.

The research was designed (project conception, development of overall research plan, and study oversight) by: I. O., B. N., G. V., M. H., B. H., K. W. B., K. R., K. B. H., A. N. and S. M. U. The research was conducted (hands-on conduct of the experiments and data collection) by: I. O., B. N., G. V., M. H., B. H., K. B. H., A. N. and S. M. U. The essential reagents or essential materials (applies to authors who contributed by providing animals, constructs, databases, etc., necessary for the research) were provided by: B. N., G. V., A. N. and K. W. B. The data were analysed by or statistical analysis was performed by: I. O., K. B. H. and S. M. U. The paper was written (only authors who made a major contribution) by: I. O., B. N., G. V., K. R., K. B. H., A. N. and S. M. U.; I. O., K. B. H. and S. M. U. had primary responsibility for the final content.

K. W. B. is clinical nutritionist/project manager and B. N. is research manager on ingredients in TINE SA R&D Centre, Norway. They have no financial interest. The other authors have no conflicts of interest, or any financial or personal interest.

References

- National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2002) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation* **106**, 3143–3421.
- Harris WS, Miller M, Tighe AP, *et al.* (2008) Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. *Atherosclerosis* **197**, 12–24.
- Harris WS, Connor WE, Alam N, *et al.* (1988) Reduction of postprandial triglyceridemia in humans by dietary *n-3* fatty acids. *J Lipid Res* **29**, 1451–1460.
- Proctor SD, Vine DF & Mamo JC (2002) Arterial retention of apolipoprotein B(48)- and B(100)-containing lipoproteins in atherogenesis. *Curr Opin Lipidol* **13**, 461–470.
- Bravo E, Napolitano M & Botham KM (2010) Postprandial lipid metabolism: the missing link between life-style habits and the increasing incidence of metabolic diseases in western countries? *Open Trans Med J* **2**, 1–13.
- Roche HM & Gibney MJ (2000) The impact of postprandial lipemia in accelerating atherothrombosis. *J Cardiovasc Risk* **7**, 317–324.
- Nordestgaard BG, Benn M, Schnohr P, *et al.* (2007) Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. *JAMA* **298**, 299–308.
- Bansal S, Buring JE, Rifai N, *et al.* (2007) Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. *JAMA* **298**, 309–316.
- Hyson D, Rutledge JC & Berglund L (2003) Postprandial lipemia and cardiovascular disease. *Curr Atheroscler Rep* **5**, 437–444.
- Schuchardt JP & Hahn A (2013) Bioavailability of long-chain omega-3 fatty acids. *Prostaglandins Leukot Essent Fatty Acids* **89**, 1–8.
- Dyerberg J, Madsen P, Moller JM, *et al.* (2010) Bioavailability of marine *n-3* fatty acid formulations. *Prostaglandins Leukot Essent Fatty Acids* **83**, 137–141.
- Neubronner J, Schuchardt JP, Kressel G, *et al.* (2011) Enhanced increase of omega-3 index in response to long-term *n-3* fatty acid supplementation from triacylglycerides versus ethyl esters. *Eur J Clin Nutr* **65**, 247–254.
- Esterbauer H, Schaur RJ & Zollner H (1991) Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. *Free Radic Biol Med* **11**, 81–128.
- European Food Safety Authority (EFSA) (2011) Scientific opinion on fish oil for human consumption. Food hygiene, including rancidity. *EFSA J* **8**, 1874.
- Council of Europe (2011) *European Pharmacopoeia*, 7th ed. Supplement 6.3. Strasbourg, France: Council of Europe.
- Albert BB, Derraik JG, Cameron-Smith D, *et al.* (2015) Fish oil supplements in New Zealand are highly oxidised and do not meet label content of *n-3* PUFA. *Sci Rep* **5**, 7928.
- Blomhoff R (2005) Dietary antioxidants and cardiovascular disease. *Curr Opin Lipidol* **16**, 47–54.
- Fierens C & Corthout J (2007) Omega-3 fatty acid preparations – a comparative study. *J Pharm Belg* **62**, 115–119.
- Jackowski SA, Alvi AZ, Mirajkar A, *et al.* (2015) Oxidation levels of North American over-the-counter *n-3* (omega-3) supplements and the influence of supplement formulation and delivery form on evaluating oxidative safety. *J Nutr Sci* **4**, e30.
- Luley C, Klein B, Hanisch M, *et al.* (1988) Fatty acid composition and degree of peroxidation in fish oil and cod liver oil preparations. *Arzneimittelforschung* **38**, 1783–1786.
- Opperman M & Benade S (2013) Analysis of the omega-3 fatty acid content of South African fish oil supplements: a follow-up study. *Cardiovasc J Afr* **24**, 297–302.
- Ottestad I, Vogt G, Retterstol K, *et al.* (2011) Oxidised fish oil does not influence established markers of oxidative stress in healthy human subjects: a randomised controlled trial. *Br J Nutr* **108**, 315–326.
- Garcia-Hernandez VM, Gallar M, Sanchez-Soriano J, *et al.* (2013) Effect of omega-3 dietary supplements with different oxidation levels in the lipidic profile of women: a randomized controlled trial. *Int J Food Sci Nutr* **64**, 993–1000.
- Sutherland WH, de Jong SA, Walker RJ, *et al.* (2002) Effect of meals rich in heated olive and safflower oils on oxidation of postprandial serum in healthy men. *Atherosclerosis* **160**, 195–203.
- Staprans I, Rapp JH, Pan XM, *et al.* (1994) Oxidized lipids in the diet are a source of oxidized lipid in chylomicrons of human serum. *Arterioscler Thromb* **14**, 1900–1905.
- Naruszewicz M, Wozny E, Mirkiewicz E, *et al.* (1987) The effect of thermally oxidized soya bean oil on metabolism of chylomicrons. Increased uptake and degradation of oxidized chylomicrons in cultured mouse macrophages. *Atherosclerosis* **66**, 45–53.
- Negre-Salvayre A, Auge N, Ayala V, *et al.* (2010) Pathological aspects of lipid peroxidation. *Free Radic Res* **44**, 1125–1171.
- Niki E, Yoshida Y, Saito Y, *et al.* (2005) Lipid peroxidation: mechanisms, inhibition, and biological effects. *Biochem Biophys Res Commun* **338**, 668–676.
- Bligh EG & Dyer WJ (1959) A rapid method of total lipid extraction and purification. *Can J Biochem Physiol* **37**, 911–917.
- Ghasemifard S, Turchini GM & Sinclair AJ (2014) Omega-3 long chain fatty acid 'bioavailability': a review of evidence and methodological considerations. *Prog Lipid Res* **56**, 92–108.
- Schram LB, Nielsen CJ, Porsgaard T, *et al.* (2007) Food matrices affect the bioavailability of (*n-3*) polyunsaturated fatty acids in a single meal study in humans. *Food Res Int* **40**, 1062–1068.
- Raatz SK, Redmon JB, Wimmergren N, *et al.* (2009) Enhanced absorption of *n-3* fatty acids from emulsified compared with encapsulated fish oil. *J Am Diet Assoc* **109**, 1076–1081.
- Garaiova I, Guschina IA, Plummer SF, *et al.* (2007) A randomised cross-over trial in healthy adults indicating improved absorption of omega-3 fatty acids by pre-emulsification. *Nutr J* **6**, 4.



34. Raatz SK, Bibus D, Thomas W, *et al.* (2001) Total fat intake modifies plasma fatty acid composition in humans. *J Nutr* **131**, 231–234.
35. Harris WS (1989) Fish oils and plasma lipid and lipoprotein metabolism in humans: a critical review. *J Lipid Res* **30**, 785–807.
36. Armand M, Pasquier B, Andre M, *et al.* (1999) Digestion and absorption of 2 fat emulsions with different droplet sizes in the human digestive tract. *Am J Clin Nutr* **70**, 1096–1106.
37. Harris WS & Muzio F (1993) Fish oil reduces postprandial triglyceride concentrations without accelerating lipid-emulsion removal rates. *Am J Clin Nutr* **58**, 68–74.
38. Hedengran A, Szecsi PB, Dyerberg J, *et al.* (2015) *n*-3 PUFA esterified to glycerol or as ethyl esters reduce non-fasting plasma triacylglycerol in subjects with hypertriglyceridemia: a randomized trial. *Lipids* **50**, 165–175.
39. Miyoshi T, Noda Y, Ohno Y, *et al.* (2014) Omega-3 fatty acids improve postprandial lipemia and associated endothelial dysfunction in healthy individuals – a randomized cross-over trial. *Biomed Pharmacother* **68**, 1071–1077.
40. Song Z, Yang L, Shu G, *et al.* (2013) Effects of the *n*-6/*n*-3 polyunsaturated fatty acids ratio on postprandial metabolism in hypertriglycerolemia patients. *Lipids Health Dis* **12**, 181.